GTS Biotech
Preclinical-stage biotechnology company focused on discovery and development of oncology and immunology therapeutics derived from natural sources. The organization pursues isolation and characterization of plant-derived bioactive compounds, preclinical efficacy and mechanism-of-action studies, and regulatory engagement for designations such as Orphan Drug and Rare Pediatric Disease.
Industries
Nr. of Employees
small (1-50)
GTS Biotech
Patents
Methods and compositions for the inhibition of the expression of PD-L1 in tumor cells
US-10894030-B2
View Details
Methods and compositions for the inhibition of the expression of PD-L1 in tumor cells
US-10894030-B2
View DetailsProducts
CTB-1 (Cinnamtannin B-1)
A plant-derived trimeric proanthocyanidin investigated for anti-proliferative effects against osteosarcoma and other cancer models; reported to act via miR-1281/PPIF pathway modulation, p53 stabilization, and PD-L1/PD-1 related mechanisms.
CTD-1
A natural compound derived from plant sources reported to have immunomodulatory and anti-inflammatory properties, including modulation of Treg/Th17 balance and activation of AMPk/mTOR signaling.
CTB-1
A groundbreaking compound primarily derived from cinnamon bark with clinically proven anti-cancer properties, selectively targeting malignant cells while minimizing harm to healthy tissues.
Cinnamtannin B-1
Cinnamtannin B-1 is a natural compound that inhibits the progression of osteosarcoma by regulating the miR-1281/PPIF axis. It has received orphan drug designation from the FDA as a treatment for osteosarcoma and rare pediatric disease designation.
CTB-1 (Cinnamtannin B-1)
A plant-derived trimeric proanthocyanidin investigated for anti-proliferative effects against osteosarcoma and other cancer models; reported to act via miR-1281/PPIF pathway modulation, p53 stabilization, and PD-L1/PD-1 related mechanisms.
CTD-1
A natural compound derived from plant sources reported to have immunomodulatory and anti-inflammatory properties, including modulation of Treg/Th17 balance and activation of AMPk/mTOR signaling.
CTB-1
A groundbreaking compound primarily derived from cinnamon bark with clinically proven anti-cancer properties, selectively targeting malignant cells while minimizing harm to healthy tissues.
Cinnamtannin B-1
Cinnamtannin B-1 is a natural compound that inhibits the progression of osteosarcoma by regulating the miR-1281/PPIF axis. It has received orphan drug designation from the FDA as a treatment for osteosarcoma and rare pediatric disease designation.
Expertise Areas
- Natural product drug discovery
- Oncology therapeutic development
- Immunotherapy and immune modulation
- Preclinical pharmacology and in vivo models
Key Technologies
- In vivo xenograft tumor models
- miRNA pathway analysis
- Cytokine profiling and immune assays
- Molecular pathway and protein-expression analysis
News & Updates
Article describing CTD-1's reported ability to modulate Treg/Th17 balance, activate AMPk/mTOR signaling, reduce pro-inflammatory cytokines, and potentially enhance antitumor immune responses.
Announcement that CTB-1 received Rare Pediatric Disease (RPD) designation from the U.S. Food & Drug Administration for pediatric osteosarcoma.
Announcement that CTB-1 was granted Orphan Drug Designation by the U.S. Food & Drug Administration for treatment of osteosarcoma.
Article describing CTD-1's reported ability to modulate Treg/Th17 balance, activate AMPk/mTOR signaling, reduce pro-inflammatory cytokines, and potentially enhance antitumor immune responses.
Announcement that CTB-1 received Rare Pediatric Disease (RPD) designation from the U.S. Food & Drug Administration for pediatric osteosarcoma.
Announcement that CTB-1 was granted Orphan Drug Designation by the U.S. Food & Drug Administration for treatment of osteosarcoma.